http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 1444 reviews. 1444 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

Claritromicina EG

Search a suitable generic or branded drugs, if you could not find the prescribed medicine. This site does not supply any medicines. It contains prices for information purposes only.
You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

Claritromicina EG uses and description

Sort by popularity
Claritromicina EG - Pharmacology: Binds to the 50S ribosomal subunit of susceptible microorganisms, resulting in inhibition of protein synthesis.

Indication: Adults Immediate-release tablets and oral suspension

Treatment of pharyngitis/tonsillitis; acute maxillary sinusitis; acute bacterial exacerbation of chronic bronchitis; community-acquired pneumonia; uncomplicated skin and skin structure infections; disseminated mycobacterial infections; Helicobacter pylori and duodenal ulcer disease when used in combination with amoxicillin and lansoprazole or omeprazole; H. pylori and active duodenal ulcer when used in combination with omeprazole or ranitidine bismuth citrate; prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection; treatment of disseminated mycobacterial infections caused by M. avium or Mycobacterium intracellulare.

ER tablets

Treatment of acute maxillary sinusitis; acute bacterial exacerbation of chronic bronchitis; community-acquired pneumonia.

Children Immediate-release tablets and oral suspension

Pharyngitis/tonsillitis; community-acquired pneumonia; acute maxillary sinusitis; acute otitis media; uncomplicated skin and skin structure infections; prevention of disseminated MAC disease in children with advanced HIV infection; treatment of M. avium or M. intercellulare.

Claritromicina EG is a macrolide antibiotic. Claritromicina EG fights bacteria in your body.

Claritromicina EG is used to treat many different types of bacterial infections affecting the skin and respiratory system. Claritromicina EG is also used together with other medicines to treat stomach ulcers caused by Helicobacter pylori.

Claritromicina EG may also be used for purposes not listed in this medication guide.

Used for: Treating infections caused by certain bacteria.

Claritromicina EG is a macrolide antibiotic. It works by stopping the growth of or killing sensitive bacteria by reducing the production of important proteins needed by the bacteria to survive.

Claritromicina EG is a macrolide antibiotic whose spectrum of activity includes many gram-positive (Staphylococcus aureus, S. pneumoniae, and S. pyogenes) and gram-negative aerobic bacteria (Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis), many anaerobic bacteria, some mycobacteria, and some other organisms including Mycoplasma, Ureaplasma, Chlamydia, Toxoplasma, and Borrelia. Other aerobic bacteria that Claritromicina EG has activity against include C. pneumoniae and M. pneumoniae. Claritromicina EG has an in-vitro activity that is similar or greater than that of erythromycin against erythromycin-susceptible organisms. Claritromicina EG is usually bacteriostatic, but may be bactericidal depending on the organism and the drug concentration.

Claritromicina EG is an antibiotic. It is used to treat certain bacterial infections of the ear, nose, throat, lungs or skin Claritromicina EG can also be used to prevent infection when you undergo certain dental procedures. Claritromicina EG is also used in combination with other medicines for gastric ulcers caused by a type of bacteria known as Helicobacter pylori (H. pylori). Claritromicina EG belongs to a group of antibiotics called the macrolides.

Oral Susceptible infections

Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 7-14 days.

Child: 7.5 mg/kg bid for 5-10 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Respiratory tract infections

Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 7-14 days.

Child: 7.5 mg/kg bid for 5-10 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Skin and soft tissue infections

Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 7-14 days.

Child: 7.5 mg/kg bid for 5-10 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Mycobacterium avium complex infections

Adult: 500 mg bid in combination with other antimycobacterials.

Child: 7.5 mg/kg bid; to be used with other antimycobacterials. May increase dose to 15 mg/kg (max: 500 mg) bid. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Leprosy

Adult: 500 mg daily as part of an alternative multidrug therapy. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Eradication of H. pylori associated with peptic ulcer disease

Adult: 500 mg bid; given in combination with another antibacterial and either a proton pump inhibitor or H 2 -receptor antagonist for 7-14 days.

Child: ≥1 yr: 7.5 mg/kg bid; may be given with another antibacterial and a proton pump inhibitor for 7 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Intravenous Respiratory tract infections

Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible.

Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Intravenous Skin and soft tissue infections

Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible.

Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Intravenous Susceptible infections

Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible.

Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval.

Indications:

Adult: PO Resp tract infections; Skin and soft tissue infections; Susceptible infections 250 mg twice daily, up to 500 mg twice daily for severe infections, for 7-14 days. Mycobacterium avium complex infections W/ other antimycobacterials: 500 mg twice daily. Leprosy As part of multidrug therapy: 500 mg/day. H. pylori infection W/ another antibacterial and either a proton pump inhibitor or H 2 antagonist: 500 mg twice daily for 7-14 days. IV Resp tract infections; Skin and soft tissue infections; Susceptible infections 500 mg twice daily for 2-5 days.

Oral Susceptible infections

Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 7-14 days.

Child: 7.5 mg/kg bid for 5-10 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Respiratory tract infections

Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 7-14 days.

Child: 7.5 mg/kg bid for 5-10 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Skin and soft tissue infections

Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 7-14 days.

Child: 7.5 mg/kg bid for 5-10 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Infections due to Mycobacterium avium complex (MAC)

Adult: 500 mg bid in combination with other antimycobacterials.

Child: 7.5 mg/kg bid; to be used with other antimycobacterials. May increase dose to 15 mg/kg (max: 500 mg) bid. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Leprosy

Adult: 500 mg daily as part of an alternative multidrug therapy. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Oral Eradication of H. pylori associated with peptic ulcer disease

Adult: 500 mg bid in combination with either a proton pump inhibitor or H 2 -receptor antagonist for 7-14 days.

Child: ≥1 yr: 7.5 mg/kg bid; may be given with another antibacterial and a proton pump inhibitor for 7 days. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Intravenous Respiratory tract infections

Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible.

Child: 1 mth–12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Intravenous Skin and soft tissue infections

Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible.

Child: 1 mth–12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval. Intravenous Susceptible infections

Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible.

Child: 1 mth–12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. CrCl (ml/min) Dosage Recommendation <30 Half the dosage or double dosing interval.

for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below:Adults (Filmtab Tablets and Granules for Oral Suspension)Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Claritromicina EG is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of Claritromicina EG in the subsequent prevention of rheumatic fever are not available at present).Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR).Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage).Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare(clarithromycin) Filmtab tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Filmtab tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain Claritromicina EG as the single antimicrobial agent are more likely to be associated with the development of Claritromicina EG resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected Claritromicina EG resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to Claritromicina EG is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children (Filmtab Tablets and Granules for Oral Suspension)Pharyngitis/Tonsillitis due to Streptococcus pyogenes. Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR)Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniaeAcute otitis media due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniaeNOTE: For information on otitis media, see Clinical Studies - Otitis Media. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.)Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulareAdults (Filmtab Tablets) Filmtab (clarithromycin extended-release tablets) are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below:Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniaeAcute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniaeCommunity-Acquired Pneumonia due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Chlamydia pneumoniae (TWAR), or Mycoplasma pneumoniae

Indications: URTI, pharyngitis and sinusitis, LRTI, bronchitis and pneumonia, skin and soft tissue infection.

H.

Pylori infection.

Infection due to Mycobacterium avium complex (MAC).

Active ingredients: Clarithromycin
Unit description, dosagePrice, USD

List of claritromicina eg brand and generic drugs

Claritromicina Zocid (Portugal)
Claritromicinã (Romania)
Claritromix (Peru)
Claritromycine
Suspension; Oral; Clarithromycin 125 mg / 5 ml
Suspension; Oral; Clarithromycin 250 mg / 5 ml
Tablet; Oral; Clarithromycin 250 mg
Tablet; Oral; Clarithromycin 500 mg
Claritromycine A (Netherlands)
Claritromycine Actavis (Netherlands)
Claritromycine Apotex (Netherlands)
Claritromycine CF (Netherlands)
Claritromycine Merck (Netherlands)
Claritromycine PCH (Netherlands)
Claritromycine Ranbaxy (Netherlands)
Claritromycine Ratiopharm (Netherlands)
Claritromycine Sandoz (Netherlands)
Claritron (Venezuela)
Claritron 500 mg x 3 Blister x 5 Tablet
Claritrox (Peru)
Claritt (Bahrain, Oman)
Claritt XL (Oman)
Claritur
Clariva (Oman)
Clarivax (Venezuela)
Clarividi (Vietnam)
Clarividi 250 mg x 2 Blister x 10 Tablet
Clarividi 500 mg x 2 Blister x 10 Tablet
Clarividi 500 x 2 Blister x 10 Tablet
Clarividi 500 x 1 chai 100 Tablet
Clarividi 500 mg x 1 chai 100 Tablet
Clarivir (India)
Clarivir 250mg TAB / 10$ 4.63
Clarivir 500mg TAB / 10$ 9.26
250 mg x 10's$ 4.63
500 mg x 10's$ 9.26
Clarivir 500 mg Tablet$ 0.09
Clarivir 250 mg Tablet$ 0.04
Clarivir Oral
Clarivir Oral 30 ml Suspension$ 0.29
Clariwin (Myanmar, Peru)
CLARIWIN Dispersible Tablet / 125mg (10 units)$ 2.22
CLARIWIN Capsule/ Tablet / 250mg (4 units)$ 1.48
CLARIWIN Capsule/ Tablet / 500mg (4 units)$ 2.63
Clariwin 250mg TAB / 4$ 1.25
Clariwin 500mg TAB / 4$ 2.22
250 mg x 4's$ 1.25
500 mg x 4's$ 2.22

Show all Claritromicina EG generic names
 
Privacy Policy
© 2003 - 2014 igenericdrugs.com All Rights Reserved
 
Disclamer